SPROUTY-2 (SPRY2) regulates receptor tyrosine kinase signalling and therefore cell growth and differentiation. In this study, we show that SPRY2 expression in colon cancer cells is inhibited by the active vitamin D metabolite 1a,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) through E-cadherin-dependent and -independent mechanisms. In turn, SPRY2 represses both basal and 1,25(OH) 2 D 3 -induced E-cadherin expression. In line with this, SPRY2 induces ZEB1 RNA and protein, but not that of other epithelial-to-mesenchymal transition inducers that repress the CDH1/E-cadherin promoter. Consistently, SPRY2 and E-cadherin protein levels inversely correlate in colon cancer cell lines and xenografted tumours. Moreover, SPRY2 knockdown by small hairpin RNA increases CDH1/E-cadherin expression and, reciprocally, CDH1/E-cadherin knockdown increases that of SPRY2. In colon cancer patients, SPRY2 is upregulated in undifferentiated high-grade tumours and at the invasive front of low-grade carcinomas. Quantification of protein expression in 34 tumours confirmed an inverse correlation between SPRY2 and E-cadherin. Our data demonstrate a tumourigenic action of SPRY2 that is based on the repression of E-cadherin, probably by the induction of ZEB1, and a reciprocal regulation of SPRY2 and E-cadherin that dictates cell phenotype. We propose SPRY2 as a candidate novel marker for high-grade tumours and a target of therapeutic intervention in colon cancer.
Introduction
Many epidemiological and animal studies indicate that the active vitamin D metabolite 1a, 25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) affords protection against colon cancer (Campbell and Adorini, 2006; Deeb et al., 2007; Eelen et al., 2007) . A causal link between vitamin D deficiency and colon cancer has recently been considered probable by the International Agency for Research on Cancer (IARC, 2008) .
We have reported that 1,25(OH) 2 D 3 inhibits the proliferation and promotes the differentiation of human colon cancer cells by the induction of the adhesion molecule E-cadherin and the antagonism of the Wnt/ b-catenin pathway (Pa´lmer et al., 2001; Aguilera et al., 2007) ). A transcriptomic analysis revealed a decrease in the level of SPROUTY-2 (SPRY2) RNA on treatment of SW480-ADH cells with 1,25(OH) 2 D 3 (5.6-fold at 4 h) (Pa´lmer et al., 2003) . SPRY2 protein is a member of a highly conserved family (SPRY1-4) of intracellular modulators of several growth factor receptors tyrosine kinase (RTK) (Cabrita and Christofori, 2008) . Its effect on RTK-Ras-ERK signalling depends strongly on receptor and cell-context (Cabrita and Christofori, 2008) . SPRY2 inhibits fibroblast growth factor extracellular signal-regulated kinase signalling activation, whereas it potentiates extracellular signal-regulated kinase activation by epidermal growth factor (EGF) in some cell types (Egan et al., 2002; Rubin et al., 2003) . Two mechanisms for this potentiation have been proposed: (a) competition with EGF receptor (EGFR) for binding to the c-Cbl E3 ubiquitin ligase by association with the endocytic adapter CIN85, which would prevent EGFR endocytosis and degradation (Wong et al., 2002; Haglund et al., 2005) ; and (b) interference with activated EGFR trafficking to late endosomes by interaction with the hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) . How SPRY2 exerts such distinct effects on fibroblast growth factor and EGF signalling is unclear.
Similarly, SPRY2 regulation is complex. SPRY2 transcription is induced by EGF, fibroblast growth factors, hepatocyte growth factor and platelet-derived growth factor, which also promotes degradation of SPRY2 protein in a negative feedback process (Cabrita and Christofori, 2008) . Conversely, transforming growth factor-b1 inhibits mouse Spry2 transcription and reduces protein stability in fibroblasts by promoting its lysosomal degradation (Ding et al., 2007) . SPRY2 expression in human cancers depends on tumour type. SPRY2 is downregulated in breast, prostate, and liver tumours and in B-cell diffuse lymphoma, which would suggest a tumour suppressive role (McKie et al., 2005; Fong et al., 2006; Lo et al., 2006; Sa´nchez et al., 2008; Frank et al., 2009) . In contrast, SPRY2 is upregulated in melanoma cell lines concomitantly to mutation of N-RAS and B-RAF (Tsavachidou et al., 2004; Bloethner et al., 2005) . Data on colon cancer are scarce and inconclusive: only one study has reported opposite changes of SPRY2 RNA levels in a low number of patients, and the tumour characteristics were not described (Lo et al., 2006) .
In this study, we show that SPRY2 decreases both the basal and 1,25(OH) 2 D 3 -induced expression of E-cadherin, leading to the inhibition of the adhesive epithelial phenotype of colon cancer cells. Consistently, SPRY2 induces the epithelial-to-mesenchymal transition gene ZEB1. In addition, we show that SPRY2 gene is inhibited by 1,25(OH) 2 D 3 in colon cancer cells in part due to the induction of E-cadherin-mediated cell adhesion. The reciprocal repression between SPRY2 and E-cadherin is substantiated by the inverse correlation of their level of expression in a panel of colon cancer cell lines and in xenografted tumours. In colon cancer patients, SPRY2 expression also correlates inversely with that of E-cadherin. Together, these data indicate that SPRY2 is a negative regulator of E-cadherin and 1,25(OH) 2 D 3 action, which promotes cell dedifferentiation and invasion. 1,25(OH) 2 D 3 decreased SPRY2 RNA expression by 50%, validating a previous transcriptomic study (Pa´lmer et al., 2003) (Figure 1a ). This decrease was even stronger at the protein level (preferentially of the upper, phosphorylated band) (Figure 1b, left) . The inhibition was specific, as the level of SPRY4 did not change (Figure 1b, right) , and it was not observed for other nuclear receptor ligands such as dexamethasone, estradiol or progesterone (Figure 1c) . A kinetics analysis showed a progressive reduction of SPRY2 protein (Figure 1d ). Supporting a general effect, 1,25(OH) 2 D 3 decreased SPRY2 expression in a panel of human colon cancer cell lines (HT29, KM12SM, DLD-1, SW1417) ( Figure 1e ). The RNA polymerase II inhibitor actinomycin D (ActD) and the translation inhibitor cycloheximide (Chx) were used to further investigate the mechanism of SPRY2 repression. Pretreatment with ActD showed that SPRY2 RNA half-life is only B40 min, which makes putative shortening by 1,25(OH) 2 D 3 difficult to assess (Supplementary Figure 1a) . To overcome this limitation, we added (Supplementary Figure 1c) . By contrast, Chx did not prevent the decrease of SPRY2 RNA when added 19 h after 1,25(OH) 2 D 3 possibly because proteins responsible for this effect were already synthesized (Supplementary Figure 1d) . Pretreatment with Chx hampered the decrease of SPRY2 protein by 1,25(OH) 2 D 3 (Supplementary Figure 2a) , whereas its addition after 1,25(OH) 2 D 3 did not prevent it (Supplementary Figure 2b ). In these experiments, the upper band of SPRY2 showed higher stability than the lower band. Together, these data suggest that 1,25(OH) 2 D 3 decreases SPRY2 protein stability and SPRY2 gene transcription, but does not alter SPRY2 RNA stability. 1,25(OH) 2 D 3 does not alter the stability of E-cadherin RNA (Pa´lmer et al., 2001) or protein (Supplementary Figure 3) . We then investigated whether the effect of SPRY2 on cell phenotype could be a consequence of a general blockade of 1,25(OH) 2 D 3 action. To this end, we first analysed the expression of vitamin D receptor (VDR), a member of the nuclear receptor superfamily that mediates all known actions of 1,25(OH) 2 D 3 (Ordo´nez-Mora´n et al., 2008) . As reported in many systems, 1,25(OH) 2 D 3 increased VDR protein (Wiese et al., 1992; Pike et al., 2007) . SPRY2 did not change basal VDR expression or its increase by ligand (Figure 2c ). Moreover, a consensus vitamin D response element (VDRE) was similarly activated by 1,25(OH) 2 D 3 in Mock and SPRY2 cells (Figure 2d ). In addition, we observed that SPRY2 did not alter the repression of c-MYC protein by 1,25(OH) 2 D 3 (Figure 2e ). Together, these results indicate that SPRY2 specifically represses the induction of an adhesive phenotype by 1,25(OH) 2 D 3 without affecting its ability to activate or repress gene expression.
E-cadherin is the main molecule responsible for intercellular adhesion in epithelia and it is induced by 1,25(OH) 2 D 3 in human colon cancer cells (Pa´lmer et al., 2001; Ordo´nez-Mora´n et al., 2008) . We examined whether it could be regulated by SPRY2. Using quantitative reverse transcription-PCR, we found the level of CDH1/E-cadherin RNA to be much lower (B70% reduction) in SPRY2 cells than in Mock cells (Figure 3a) . Similarly, the basal expression of E-cadherin protein was also lower in SPRY2 cells than in Mock cells, and 450% reduction was found in the presence of 1,25(OH) 2 D 3 (Figure 3b ). Again, 1,25(OH) 2 D 3 decreased the amount of exogenous SPRY2 protein. These results were confirmed by immunofluorescence analyses, which showed a reduction of plasma membrane E-cadherin and of intercellular adhesion in SPRY2 cells as compared with Mock cells after 1,25(OH) 2 D 3 treatment (Figure 3c ).
To search for an explanation for the inhibition of E-cadherin expression in SPRY2 cells, we analysed the expression of epithelial-to-mesenchymal transition inducers that are transcriptional repressors of CDH1/ E-cadherin (Peinado et al., 2007) . In line with its inhibitory effect on E-cadherin, SPRY2 increased the expression of ZEB1 RNA ( Figure 3d ). In contrast, no changes were found for SNAI1, SNAI2/SLUG or ZEB2. The increase of ZEB1 protein by SPRY2 was confirmed by western blot analysis ( Figure 3e ). In accordance with the upregulation of ZEB1 by SPRY2, the activity of CDH1/E-cadherin promoter was much lower in SPRY2 cells than in Mock cells ( Figure 3f ). ZEB1 knockdown by small hairpin RNA (shRNA) increased E-cadherin protein expression in Mock cells, but did not alter SPRY2 level ( Supplementary Figures 4a and b) . In cells expressing ectopic SPRY2, ZEB1 silencing by shRNA was ineffective perhaps because SPRY2 increases ZEB1 transcription. Because ZEB1 decreases E-cadherin, it is possible that SPRY2 by augmenting ZEB1 transcription decreases E-cadherin (Supplementary Figure 4c ).
E-cadherin and SPRY2 mutually repress in colon cancer cells
We studied the expression of E-cadherin and SPRY2 proteins in a panel of human colon cancer cell lines. A strong inverse relation was found, as the cell lines with high E-cadherin contained low SPRY2 levels (KM12SM, HT29 and SW1417), whereas those with low E-cadherin contained high SPRY2 levels (SW480-R, LS174T and rat CT26) ( Figure 4a ). Remarkably, no inverse relation was found in SW48 cells that express E-cadherin, but nevertheless show little adhesiveness due to the mutation of p120-catenin, a known regulator of E-cadherin protein stability and localization (Ireton et al., 2002) . In contrast to what happened with SPRY2, the level of SPRY4 expression was unrelated to that of E-cadherin in the panel of cell lines studied (Supplementary Figure 5a ).
The possibility that the repression of SPRY2 by 1,25(OH) 2 D 3 could be linked to the induction of E-cadherin was first studied in dose curve and kinetics experiments using SW480-ADH cells. Similarity was found between both 1,25(OH) 2 D 3 effects (Figures 4b  and c) . To further investigate this, we studied SPRY2 expression in SW480-ADH cells stably expressing an exogenous E-cadherin gene (SW480-ADH-E-cadh). These cells contain high levels of E-cadherin and show strong adhesiveness (Aguilera et al., 2007) . In the absence of 1,25(OH) 2 D 3 , the level of SPRY2 RNA and protein was lower in SW480-ADH-E-cadh cells than in Mock cells (Figures 4d and e) . This suggested that E-cadherin, or the intercellular adhesion that it causes, may mediate the inhibition of SPRY2. In line with this idea, highly tumourigenic SW480-R cells (that contained very low E-cadherin and VDR levels and, similar to SW480-ADH cells, were derived from the parental SW480 cell line (Tomita et al., 1992; Pa´lmer et al., 2001) ) showed strong SPRY2 expression (Supplementary Figure 5b) . These data however did not discriminate whether E-cadherin or intercellular adhesion itself was responsible for SPRY2 inhibition. To solve this, we used LS174T cells that lack E-cadherin expression due to a mutation (Efstathiou et al., 1999) . In LS174T cell cultures, the expression of SPRY2 RNA and protein was lower (40%) at high confluence than at lower confluence (Figures 4f and g ). This result emphasizes the importance of cell adhesion for SPRY2 repression. Interestingly, 1,25(OH) 2 D 3 further reduced SPRY2 RNA and protein expression in SW480-ADH-E-cadh (Figures 4d and e) , and SPRY2 protein expression in DLD-1 and KM12SM cells (Supplementary Figure 5c ) without affecting the high level of E-cadherin RNA or protein in these cell lines. This indicates that at least part of the repressive effect of Mutual regulation of SPROUTY-2 and E-cadherin A Barbáchano et al 1,25(OH) 2 D 3 on SPRY2 is independent of E-cadherin induction.
We next examined the effect of CDH1/E-cadherin on SPRY2 expression, and vice versa. To improve our analysis of the effect of E-cadherin knockdown in SW480-ADH cells that express low basal levels, we used highly confluent cultures. CDH1/E-cadherin knockdown by shRNA in three colon cancer cell lines (SW480-ADH, HT29, DLD-1) decreased intercellular adhesion ( Figure 5a ) and increased the level of SPRY2, preferentially of the upper band (Figure 5b ) but not that of SPRY1, 3 or 4 (Supplementary Figure 6a) . ZEB1 protein expression increased only weakly in CDH1/Ecadherin knockdown SW480-ADH cells and was not detected in HT29 or DLD-1 cells (Figure 5c ).
Reciprocally, SPRY2 knockdown increased E-cadherin expression in SW480-ADH cells (Figure 6a ) without affecting that of SPRY1, 3 or 4 (Supplementary Figure 6b) . 1,25(OH) 2 D 3 further reduced SPRY2 expression in SPRY2 shRNA cells, leading to higher E-cadherin level (Figure 6a ). SPRY2 shRNA cells showed slightly increased intercellular adhesion in both the absence and the presence of 1,25(OH) 2 D 3 (Figure 6b ). The slight decrease in ZEB1 when SPRY2 is silenced (Figure 6c ) is consistent with a role for SPRY2 in increasing ZEB1 transcription, as suggested by the inability of ZEB1 shRNA to silence its expression in SPRY2-expressing cells. Collectively, these results show a reciprocal regulation of SPRY2 and E-cadherin in colon cancer cells. Both are controlled by 1,25(OH) 2 D 3 , which represses SPRY2 and induces E-cadherin expression.
Expression of SPRY2 and E-cadherin inversely correlate in human colon tumours
To investigate SPRY2 expression in human colon tumours, we first studied immunodeficient mice xenografted with SW480-ADH cells expressing haemagglutinin (HA)-tagged murine Snail1 (SNAIL-HA cells) (Pa´lmer et al., 2004) . As expected from the repressive effect of SNAIL1 on the CDH1/E-cadherin promoter (Batlle et al., 2000; Cano et al., 2000) , in these tumours, the expression of Snail1-HA and of E-cadherin were mutually exclusive (Figures 7a-c) . We found coincident expression of SPRY2 and Snail1-HA (Figures 7d-f) , and, in contrast, downregulation of SPRY2 in tumour areas showing high levels of E-cadherin protein (Figures  7g-i) . These data indicate an inverse correlation between the expression of E-cadherin and SPRY2 in xenografted tumours.
Next, we analysed biopsies from human colon cancer patients. First, we studied the expression of E-cadherin and SPRY2 in a panel of adenocarcinomas of distinct differentiation grades (Figures 8a-f) . Low-grade tumours with strong cytokeratin staining showed high levels of E-cadherin and low levels of SPRY2 (Figures  8g and j) . In contrast, high-grade tumours that had weak cytokeratin staining showed low levels of E-cadherin and high levels of SPRY2 in carcinoma cells (Figures 8i and l) . Moderately differentiated tumours (G2) displayed intermediate levels of E-cadherin and decreased SPRY2 expression (Figures 8h and k) . The inverse correlation between E-cadherin and SPRY2 was particularly strong in poorly differentiated neuroendocrine colon carcinomas (Supplementary Figure 7) . Remarkably, in low-grade (G1) tumours SPRY2 was upregulated at the invasion front, in cells that had escaped from the tumour mass (Figures 8m and n) . SPRY2 and E-cadherin protein expression was then quantified by immunofluorescence analysis in duplicate tumour samples spotted on a tissue microarray (Supplementary Information). Tumours from 34 patients were informative. A scattergram showing the quantification of fluorescence revealed a significant inverse correlation between SPRY2 and E-cadherin expression (Spearman r ¼ À0.42, P ¼ 0.013) (Figure 9a ). As a subset of tumours contained low levels of SPRY2 and E-cadherin, putatively due to other factors, no tumours were found with concomitant high expression of these two proteins (Figure 9a ). Splitting the tumours into two groups by the median value of E-cadherin fluorescence further confirmed the inverse correlation (KruskalWallis test, P ¼ 0.003) (Figure 9b) . Moreover, the comparative analysis of SPRY2 expression and several clinico-pathological parameters (Supplementary  Table 1 ) revealed a strong trend with borderline significance between SPRY2 upregulation and histological grade (Figure 9c ).
Discussion
Our study reveals a tumourigenic activity of SPRY2 in human colon cancer based on its capacity to inhibit E-cadherin expression. In addition, we demonstrate that 1,25(OH) 2 D 3 downregulates SPRY2 and that SPRY2 and E-cadherin have opposite functions in controlling cell differentiation (Figure 10 ). These effects strongly indicate that SPRY2 promotes the tumourigenic phenotype of colon carcinoma cells. Further supporting this, 
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SPRY2 is upregulated in high-grade tumours and at the invasion front of low-grade tumours.
The repression of E-cadherin is critical for tumourigenesis. E-cadherin dysfunction promotes tumour progression and metastasis by several mechanisms that include loss of intercellular adhesion, induction of epithelial-to-mesenchymal transition, anoikis resistance, and gain of invasion and proliferative capacity. This is 
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A Barbáchano et al explained by the potential of E-cadherin to inhibit mitogenic signalling from EGFR and other growth factor receptors and the Wnt/b-catenin pathway, and to maintain the differentiated epithelial phenotype through the regulation of intercellular adhesion and multiple transcription factors (Frixen et al., 1991; Vleminckx et al., 1991; Miyaki et al., 1995; Perl et al., 1998; Christofori and Semb, 1999; Qian et al., 2004; Perrais et al., 2007; Jeanes et al., 2008; Onder et al., 2008) . E-cadherin downregulation by SPRY2 is found at both RNA and protein levels, and correlates with the upregulation of ZEB1 RNA and protein. This epithelial-to-mesenchymal transition inducer is a transcriptional repressor of CDH1/E-cadherin and other epithelial genes and may thus mediate the inhibitory effect of SPRY2. The increase of E-cadherin expression upon ZEB1 knockdown supports this notion. Unfortunately, transfected ZEB1 shRNA did not decrease ZEB1 expression in SPRY2 cells in repeated attempts, perhaps due to its induction by exogenous SPRY2. The tumourigenic activity of SPRY2 is emphasized by the recent findings that ZEB1 inhibits cell polarity and differentiation and is associated with tumour cell migration, invasion and metastasis, in particular in colon carcinoma (Schmalhofer et al., 2009) . Our data show that 1,25(OH) 2 D 3 increases E-cadherin expression at least in part through SPRY2 downregulation. Because 1,25(OH) 2 D 3 inhibits SPRY2 in colon cancer cells even in the absence of E-cadherin, as occurs in E-cadherin-deficient LS174T cells, we con- clude that SPRY2 is repressed by this pleiotropic hormone through both E-cadherin-dependent and -independent mechanisms. The data obtained using ActD and Chx and the decrease of exogenous SPRY2 by 1,25(OH) 2 D 3 favour an indirect regulation mediated by intermediary proteins that affect SPRY2 transcription and SPRY2 protein stability. The intimate basis of E-cadherin-dependent regulation is unknown, but may be responsible for, or contribute to these mechanisms.
The reciprocal repression between SPRY2 and Ecadherin is substantiated by the inverse relation of their expression levels in a panel of colon cancer cell lines. In addition, the use of shRNA showed their mutual downregulation. Dose curves and kinetics of E-cadherin induction and SPRY2 repression by 1,25(OH) 2 D 3 are similar, suggesting that the two effects are initially independent, although they may later be linked and enhanced by the mutual regulation of E-cadherin and SPRY2. Thus, the finding that SPRY2 expression decreases with cell confluence suggests that this effect relies on adhesion-dependent signalling. In line with this hypothesis, it has recently been shown that high cell density activates p38MAPK, which phosphorylates and activates Siah2 ubiquitin ligase and so decreases SPRY2 levels (Swat et al., 2009) . It is to be noted that 1,25(OH) 2 D 3 has recently been reported to transiently activate p38MAPK in many cell lines of human and rodent origin. Mutual downregulation between E-cadherin and ligandactivated EGFR has been described (Qian et al., 2004) . Mutation of E-cadherin in diffuse-type gastric carcinoma associates with increased activation of EGFR (Bremm et al., 2008) . In non-small cell lung cancer, E-cadherin has an important function in prognosis and progression and interacts with EGFR. In this neoplasia, E-cadherin and ZEB1 expression correlate with sensitivity to the EGFR inhibitor genitinib (Witta et al., 2006) . Similarly, colorectal and pancreatic cell lines with mutated or no E-cadherin are also insensitive to the EGFR inhibitor erlotinib (Buck et al., 2007) . Our results suggest that SPRY2, which potentiates extracellular signal-regulated kinase activation by EGF (Egan et al., 2002; Rubin et al., 2003) , is a good candidate to mediate the crosstalk between ligand-activated EGFR and both E-cadherin and 1,25(OH) 2 D 3 /VDR. In addition, our study supports a master role of 1,25(OH) 2 D 3 in promoting differentiation and preventing excessive proliferation of colon cancer cells through the repression of SPRY2 and the induction of CDH1/E-cadherin.
The effects of SPRY2 revealed here, its pattern of expression that is opposite to that of E-cadherin, and its upregulation in high-grade tumours strongly argue in favour of a tumourigenic activity in human colon cancer. This contrasts with the proposed tumour suppressor activity of SPRY2 in breast, prostate and lung cancer on the basis of its decreased expression, as compared with normal tissue (McKie et al., 2005; Fong et al., 2006; Lo et al., 2006; Sa´nchez et al., 2008; Frank et al., 2009) . Concordantly with our results, a meta-analysis of data available at the Oncomine database supports that SPRY2 expression is higher in colon tumours than in other neoplasias (Rhodes et al., 2004) (Supplementary Figure 8) . In summary, SPRY2 has an unanticipated tumourigenic activity and is a potential marker of malignancy and pharmacological target in colon cancer.
Materials and methods

Cells and cell culture
Human colon cancer cell lines SW480-ADH and SW480-R, cells (Pa´lmer et al., 2001) , HT29, DLD-1, KM12SM (provided by Dr A Fabra, Barcelona), SW1417 and LS174T, human 293T cells and rat intestine cell line CT26 were cultured in Dulbecco's modified Eagle's medium plus 10% fetal bovine serum (Invitrogen, Paisley, UK). SW480-ADH-E-cadh cells were previously described (Aguilera et al., 2007) . All experiments using 1,25(OH) 2 D 3 (provided by Dr R Bouillon and A Verstuyf, Leuven, Belgium, and Dr JP van de Velde, Weesp, The Netherlands) were performed in medium supplemented with charcoal-treated serum.
Antibodies and reagents
We used primary mouse monoclonal antibodies against E-cadherin (BD Transduction Laboratories, San Jose, CA, USA), c-MYC (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-40), AU5 (Covance, Emeryville, CA, USA), SPRY2 (Abnova, Taipei, Taiwan), Pan-cytokeratin (Novocastra, Newcastle upon Tyne, UK); rat monoclonal antibodies against VDR (Chemicon, Temecula, CA, USA) and HA (BABCO-Covance, Princeton, NJ, USA); rabbit polyclonal antibodies against SPRY2 (Upstate, Lake Placid, NY, USA), SPRY1, SPRY3 and SPRY4 (Abcam, Cambridge, UK); and goat polyclonal antibodies against ZEB1, b-actin and Lamin B (Santa Cruz Biotechnology, sc-10572, sc-1616 and sc-6216, respectively) . The following secondary antibodies were used: Alexa 488-conjugated goat anti-mouse and goat anti-rabbit immunoglobulin-G (H þ L) (Molecular Probes-Invitrogen, Paisley, UK) and Alexa 546-conjugated goat anti-mouse, goat anti-rabbit and goat anti-rat immunoglobulin-(H þ L) (Molecular ProbesInvitrogen). Nuclei were stained using 4,6-diamidino-2-phenylindole (Molecular Probes-Invitrogen). Chx and ActD were from Sigma (St Louis, MO, USA). 
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A Barbáchano et al Transfection Cells were transfected using the jetPEI reagent (PolyPlus Transfection, Illkirch, France). Firefly (Luc) and Renilla reniformis luciferase (Rluc) activities were measured separately using the Dual Luciferase reagent kit (Promega, Madison, WI, USA). Luc activity was normalized to the Rluc activity. All experiments were performed in quadruplicate. The promoter construct for CDH1/E-cadherin was as previously reported (Pa´lmer et al., 2001) . The 4XVDRE-DR3-Tk-Luc construct was provided by Dr C Carlberg (University of Luxembourg). Mock and SPRY2 cells were generated by stable transfection of SW480-ADH cells with pCEFL-KZ-AU5 or pCEFL-KZ-AU5-hSPRY2 plasmids (Martı´nez et al., 2007) . 293T cells were transfected with pcDNA3-ZEB1 expression plasmid provided by Dr A Garcı´a de Herreros (Instituto Municipal de Investigacio´n Me´dica, Barcelona).
Gene silencing
To knock-down SPRY2 cells were infected with lentiviral particles containing a U6 promoter driving an shRNA targeting the respective RNA. Mission shRNA lentiviral particles against human SPRY2 or scramble negative control (Sigma) were used. For E-cadherin knock-down we used constructs belonging to the MISSION TRC shRNA library (Sigma, provided by Dr E Batlle, University of Barcelona). ZEB1 knock-down was performed by transfection with pSUPER shZEB1 kindly provided by Dr A Garcı´a de Herreros.
Quantitative RT-PCR Total cellular RNA was purified using RNeasy mini kit (Qiagen, Hilden, Germany). Primers used are listed in Supplementary 
Western blot
Proteins were separated by SDS-polyacrylamide gel electrophoresis. After blotting onto a polyvinylidene difluoride membrane, proteins were revealed after the ECL technique (Amersham, Buckinghamshire, UK). Different exposure times of the films were used to ensure that bands were not saturated. Quantification of the films was performed by densitometry using ImageJ software (Bethesda, MD, USA).
Immunofluorescence and confocal microscopy of cells and tissues Cells were fixed in methanol at À20 1C for 3 min and then washed four times in phosphate-buffered saline. Cells were incubated with the primary antibodies diluted in phosphatebuffered saline for 1 h at 37 1C. After four washes in phosphate-buffered saline, the cells were incubated with secondary antibodies for 45 min at room temperature, washed three times in phosphate-buffered saline and mounted using Prolong Gold antifade reagent (Molecular Probes-Invitrogen). Conventional fixed and paraffin-embedded sections of human tumours or tumours generated by SNAIL-HA cells in immunodeficient scid mice (Pa´lmer et al., 2004) were prepared and immunolabelled as described elsewhere (Silva-Vargas et al., 2005) . Briefly, antigens were retrieved by microwaving in 10 mM citrate buffer (pH 6.0) for 10 min and permeabilized with 0.2% Triton X-100 (Sigma). Nonspecific binding was blocked by incubating the sections in 10% bovine serum albumin (Sigma) for 1 h. Cell imaging was performed on a Figure 9 The levels of SPRY2 and E-cadherin expression correlate negatively in human colon carcinomas. E-cadherin and SPRY2 protein expression was analysed by immunofluorescence in serial samples of 34 colon carcinoma patients collected in a tissue microarray. Quantification was performed as described in Material and methods section. Leica TCS SP5 DMI6000 microscope (Leica, Wetzlar, Germany) using argon ion (488 nm), HeNe (543 nm) and violet diode (405 nm) lasers. Images were acquired sequentially by direct register using Leica Confocal Software (LAS AF).
Immunofluorescence signals were quantified as described in Supplementary Information. SNAIL-HA cells were injected in severe immunodeficient female scid mice obtained from The Jackson Laboratories (Bar Harbour, ME, USA) (Pa´lmer et al., 2004) . The maintenance and handling of animals were as recommended by the European Union (ECC Directive of 24 November 1986, 86/609/EEC) and all experiments were approved by the Animal Experimentation Committee at our Instituto de Investigaciones Biome´dicas, Madrid. Every effort was made to minimize animal suffering and reduce the number of animals used.
Patients were considered sporadic cases because no clinical antecedents of Familial Adenomatous Polyposis were reported, and those with clinical criteria of hereditary non-polyposis colorectal cancer (Amsterdam criteria) were excluded. All patients of the study gave written informed consent. The protocol was approved by the Research Ethics Board of Hospital Vall d'Hebron, Barcelona.
Other methods
The remaining materials and methods section is provided as Supplementary Information. 
